There are currently 77 clinical trials in Arlington, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Clinical Research Institute, Texas Clinical Research Institute, Llc, Texas Retina Associates and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Recruiting
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/24/2025
Locations: Arlington Center for Dermatology ( Site 0045), Arlington, Texas
Conditions: Hidradenitis Suppurativa
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
07/24/2025
Locations: Dallas Renal Group - Mansfield, Arlington, Texas +1 locations
Conditions: Proteinuric Kidney Disease
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Recruiting
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Atea Study Site, Arlington, Texas
Conditions: HEPATITIS C VIRUS CHRONIC INFECTION
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Recruiting
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well peopl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/23/2025
Locations: Texas Clinical Research Institute ( Site 0126), Arlington, Texas
Conditions: Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Recruiting
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Arlington Research Center, inc., Arlington, Texas
Conditions: Moderate to Severe Genital Psoriasis
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
Recruiting
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/22/2025
Locations: Cedar Health Research LLC, Arlington, Texas
Conditions: Alzheimer Disease
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Recruiting
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug fo... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/22/2025
Locations: Arlington Research Center, Inc /ID# 253805, Arlington, Texas
Conditions: Hidradenitis Suppurativa
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Recruiting
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Urology Partners of North Texas (UPNT), Arlington, Texas
Conditions: Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with the signs and symptoms of moderate to severe HS . Lutikizumab is an investigational drug being developed for the treatment of HS. During Period 1 o... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/21/2025
Locations: Arlington Research Center, Inc /ID# 263895, Arlington, Texas
Conditions: Hidradenitis Suppurativa
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Recruiting
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Arlington Cancer Center, Arlington, Texas
Conditions: Non-small Cell Lung Cancer
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Recruiting
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants. ABBV-CLS-628 is an investigational drug being developed for the treatment of ADPKD. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. There is a 1 in... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/21/2025
Locations: Arlington Nephrology /ID# 270494, Arlington, Texas
Conditions: Autosomal Dominant Polycystic Kidney Disease
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
07/21/2025
Locations: Arlington Research Center, Inc /ID# 266330, Arlington, Texas
Conditions: Atopic Dermatitis